InSphero CEO and Co-Founder Jan Lichtenberg Appointed to Board of Directors of the Society for Laboratory Automation and Screening (SLAS)
Brings extensive experience as an entrepreneur and a technical disruptor at the intersection of 3D in vitro technologies and automation. PDF Version
Schlieren, Switzerland – March 16, 2021 InSphero AG, the pioneer of 3D cell-based assay technology, today announced that CEO and co-founder Jan Lichtenberg, PhD has been appointed to the board of directors of the Society for Laboratory Automation and Screening (SLAS). SLAS is an international professional society of academic, industry and government life sciences researchers and developers and providers of laboratory automation technology.
“Since its founding more than a decade ago, SLAS has played an integral role in advancing the life sciences industry,” said Dr. Lichtenberg. “During the early days of InSphero, SLAS offered us a platform to communicate the value we offered to customers and technology partners. This opportunity to network with fellow entrepreneurs and technology scouts from big pharma and biotech contributed to the rapid growth of InSphero. I am honored to now be a board member. In this role, I look forward to helping the organization grow and serving as an advocate for start-up organizations, as they play a crucial role – together with academia and established companies – in pushing science and technology further.”
SLAS board members are representative of the diverse SLAS membership and are responsible for strategic leadership of the society and providing guidance on the future direction of the society and its programs. Dr. Lichtenberg will serve as secretary in 2021, vice president next year and then assume the role of president in 2023.
“We are excited to welcome Jan to our board of directors,” said Vicki L. Loise, Chief Executive Officer of SLAS. “As a microfluidics engineer and entrepreneur, he saw a critical need for the combination of 3D cell technology and automation to deliver more physiologically relevant insights for drug discovery and development. With this vision, it is no surprise that InSphero quickly became an industry leader. With his background, Jan will be a valuable board member, furthering our support of laboratory automation start-ups as well as our leading-edge educational programming.”
For more information about InSphero Leadership, visit https://insphero.com/leadership.
# # # #
InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.
Learn more at www.insphero.com. Follow the company on Twitter and LinkedIn.
Dr. Frank Junker
InSphero Chief Business Officer
Phone +41 44 5150490